Literature DB >> 26137250

Ophiopogon japonicus strains from different cultivation regions exhibit markedly different properties on cytotoxicity, pregnane X receptor activation and cytochrome P450 3A4 induction.

LE-LE Ge1, Lian-DI Kan1, Zheng-Bing Zhuge1, K E Ma1, Shu-Qing Chen2.   

Abstract

Maidong, known as Ophiopogon japonicus, is one of the two basic ingredients of Shenmai injection, which is a widely used herbal preparation in traditional Chinese medicine (TCM) for the treatment of atherosclerotic coronary heart disease and viral myocarditis. Previously, the ethanol extract of Maidong activated the pregnane X receptor (PXR) signaling pathway and induced the cytochrome P450 3A4 (CYP3A4) reporter gene and raised the concern of herb-drug interactions (HDIs) when Maidong was used in combination with prescribed drugs metabolized by CYP3A4. Therefore, the present study further investigated and compared the differences of the ethanol and aqueous extracts (ee- and ae-, respectively) of two Maidong strains, known as Zhe Maidong (ZM) and Chuan Maidong (CM). Cytotoxicity, PXR activation and CYP3A4 induction by the 3-(4,5)-dimethylthiahiazo-(-z-y1)-3,5-diphenytetrazoliumromide assay, reporter gene assay and reverse transcription-quantitative polymerase chain reaction analysis were examined. The observations showed that ee-ZM demonstrated a significantly higher cytotoxicity, a relatively weaker PXR activation capability and a markedly stronger CYP3A4-inducing capacity than ee-CM. Compared to ae-CM, ae-ZM exhibited only a slight or no difference on cytotoxicity and CYP3A4 induction, while a significant lower level of PXR activation was apparent. Collectively, Maidong from different producing areas possess different properties upon cytotoxicity and the drug-metabolizing enzyme inducing effect, and attention should be paid to the selection of Maidong strains from different planting regions into TCM preparations for reducing potential adverse reactions and HDIs.

Entities:  

Keywords:  Ophiopogon japonicus; cytochrome P450 3A4; herb-drug interactions; pregnane X receptor; traditional Chinese medicine

Year:  2015        PMID: 26137250      PMCID: PMC4467266          DOI: 10.3892/br.2015.443

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  26 in total

1.  Potential metabolic interaction between St. John's wort and theophylline.

Authors:  A Nebel; B J Schneider; R K Baker; D J Kroll
Journal:  Ann Pharmacother       Date:  1999-04       Impact factor: 3.154

2.  PXR-mediated transcriptional activation of CYP3A4 by cryptotanshinone and tanshinone IIA.

Authors:  Chunna Yu; Shanshan Ye; Hongying Sun; Yao Liu; Lingbo Gao; Chaofeng Shen; Shuqing Chen; Su Zeng
Journal:  Chem Biol Interact       Date:  2008-09-02       Impact factor: 5.192

3.  Association of Ginkgo biloba with intracerebral hemorrhage.

Authors:  M K Matthews
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

4.  Chinese herbs and warfarin potentiation by 'danshen'.

Authors:  C M Yu; J C Chan; J E Sanderson
Journal:  J Intern Med       Date:  1997-04       Impact factor: 8.989

5.  St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor.

Authors:  L B Moore; B Goodwin; S A Jones; G B Wisely; C J Serabjit-Singh; T M Willson; J L Collins; S A Kliewer
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

6.  Lignans, bacteriocides and organochlorine compounds activate the human pregnane X receptor (PXR).

Authors:  Miriam N Jacobs; Gail T Nolan; Steven R Hood
Journal:  Toxicol Appl Pharmacol       Date:  2005-12-01       Impact factor: 4.219

7.  Regulation of human pregnane X receptor and its target gene cytochrome P450 3A4 by Chinese herbal compounds and a molecular docking study.

Authors:  Ya-He Liu; Sui-Lin Mo; Hui-Chang Bi; Bing-Fang Hu; Chun Guang Li; Yi-Tao Wang; Ling Huang; Min Huang; Wei Duan; Jun-Ping Liu; Ming Qian Wei; Shu-Feng Zhou
Journal:  Xenobiotica       Date:  2010-11-30       Impact factor: 1.908

8.  Characterization of homoisoflavonoids in different cultivation regions of Ophiopogon japonicus and related antioxidant activity.

Authors:  Yining Lin; Danni Zhu; Jin Qi; Minjian Qin; Boyang Yu
Journal:  J Pharm Biomed Anal       Date:  2010-02-18       Impact factor: 3.935

9.  Potentiation of warfarin by dong quai.

Authors:  R L Page; J D Lawrence
Journal:  Pharmacotherapy       Date:  1999-07       Impact factor: 4.705

10.  Identification of the active components in Shenmai injection that differentially affect Cyp3a4-mediated 1'-hydroxylation and 4-hydroxylation of midazolam.

Authors:  Caiwen Zeng; Fang He; Chunhua Xia; Hong Zhang; Yuqing Xiong
Journal:  Drug Metab Dispos       Date:  2013-01-22       Impact factor: 3.922

View more
  5 in total

1.  58-F, a flavanone from Ophiopogon japonicus, prevents hepatocyte death by decreasing lysosomal membrane permeability.

Authors:  Xiaofeng Yan; Tingjie Ye; Xudong Hu; Pei Zhao; Xiaoling Wang
Journal:  Sci Rep       Date:  2016-06-16       Impact factor: 4.379

2.  HMGB1 release by H2O2-induced hepatocytes is regulated through calcium overload and 58-F interference.

Authors:  Pei Zhao; Tingjie Ye; Xiaofeng Yan; Xudong Hu; Ping Liu; Xiaoling Wang
Journal:  Cell Death Discov       Date:  2017-04-10

3.  De novo assembly and annotation of the Zhe-Maidong (Ophiopogon japonicus (L.f.) Ker-Gawl) transcriptome in different growth stages.

Authors:  Huijun Liu; Ying Wang; Tingzhang Wang; Xuhui Ying; Rongrong Wu; Huan Chen
Journal:  Sci Rep       Date:  2017-06-15       Impact factor: 4.379

4.  Toxic Constituents Index: A Toxicity-Calibrated Quantitative Evaluation Approach for the Precise Toxicity Prediction of the Hypertoxic Phytomedicine-Aconite.

Authors:  Ding-Kun Zhang; Rui-Sheng Li; Xue Han; Chun-Yu Li; Zhi-Hao Zhao; Hai-Zhu Zhang; Ming Yang; Jia-Bo Wang; Xiao-He Xiao
Journal:  Front Pharmacol       Date:  2016-06-17       Impact factor: 5.810

5.  Chaihu-Shugan-San Reinforces CYP3A4 Expression via Pregnane X Receptor in Depressive Treatment of Liver-Qi Stagnation Syndrome.

Authors:  Zehui He; Rong Fan; Chunhu Zhang; Tao Tang; Xu Liu; Jiekun Luo; Hanjin Cui; Yang Wang; Ruohuang Lu; Pingping Gan
Journal:  Evid Based Complement Alternat Med       Date:  2019-10-31       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.